Aragon Pharmaceuticals, Inc.

Merck + Co., Inc.

Genentech, Inc.

Seragon Pharmaceuticals, Inc.

Celine Bonnefous

Nicholas D Smith

Jackaline Dalgard Julien

Steven P Govek

Mehmet Kahraman

Johnny Yasuo Nagasawa

Andiliy Gokching Lai

Jean-Michel Andre Vernier

Karensa L Douglas

John Howard Hutchinson

Sander G Mills

Lihu Yang

Alexander Pasternak

Benito Munoz

Brian Andrew Stearns

Jeannie M Arruda

Bowei Wang

Theodore M Kamenecka

Brian T Campbell

Essa H Hu

Stephen D Goble

Mark R Herbert

Xiumin Zhao

Peter Charles Astles

Jean Michel Vernier

Rowena Villanueva Cube

Stephen Richard Baker

Martine Keenan

Adam Jan Sanderson

Jackaline D Julien

Described herein are compounds that are androgen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such androgen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon androgen receptors.

Androgen receptor modulators and uses thereof

Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.

Polycyclic estrogen receptor modulators and uses thereof

Estrogen receptor modulators and uses thereof

Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.

Fluorinated estrogen receptor modulators and uses thereof

Cyclopentyl compounds linked to a benzoxazinyl group through an amido moiety utilizing the ring nitrogen of the benzoxazine, and further substituted with a heterocyclic moiety, such compounds represented by formula I: which are used to modulate the CCR-2 chemokine receptor to prevent or treat inflammatory and immunoregulatory disorders and diseases, allergic diseases, atopic conditions including allergic rhinitis, dermatitis, conjunctivitis, and asthma, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis; and pharmaceutical compositions comprising these compounds and the use of these compounds and compositions.

Benzoxazinyl-amidocyclopentyl-heterocyclic modulators of chemokine receptors

Compounds comprising an aza-cyclic portion and an aromatic portion linked via a sulphur atom are disclosed. The compounds disclosed are selective modulators of beta 4 subtype nicotinic acetylcholine receptors and are useful for the treatment of dysfunctions of the central and autonomic nervous systems.

Aza-cyclic compounds as modulators of acetylcholine receptors

Phenyl compounds substituted at the 1-position with a fused bicyclo moeity formed from a five-membered heterocycle fused to a six-membered carbocycle, to a six-membered aryl, or to a six-membered hetaryl, and further optionally substituted at the 3,4 positions, are mGluR5 modulators useful in the treatment of psychiatric and mood disorders such as, for example, schizophrenia, anxiety, depression, and panic, as well as in the treatment of pain and other diseases.

Metabotropic glutamate receptor-5 modulators

Growing community of inventors

San Diego, CA, United States of America

Celine Bonnefous